Nexien BioPharma, Inc.
NXEN · OTC
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.16 | -0.13 | 0.15 | -0.04 |
| FCF Yield | -2.04% | -6.75% | -0.75% | -0.97% |
| EV / EBITDA | -70.21 | -32.23 | -98.64 | -22.32 |
| Quality | ||||
| ROIC | 19.03% | 0.00% | 0.00% | 131.21% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.43 | 0.73 | 0.29 | 0.13 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 54.55% | -210.37% | 15.17% | 48.07% |
| Safety | ||||
| Net Debt / EBITDA | -25.67 | -14.55 | -20.58 | -4.79 |
| Interest Coverage | -0.91 | -1.56 | -0.96 | -2.89 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |